Business
Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences
Kuros Biosciences to provide investor updateat Octavian and Baader Bank Conferences Schlieren (Zürich), Switzerland, January 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced a series of milestones including key IDN (Integrated Delivery Network) health system approvals, significant regulatory approval, and published preclinical evidence supporting the continued adoption and global expansion of MagnetOs™, which are going to be pr
About this update from Baader Bank Ag
[{"type":"image","alt":"Kuros Biosciences AG","displaySize":"","headline":null,"caption":"Kuros Biosciences AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":53,"url":"https://media.zenfs.com/en/globenewswire.com/53e70503ab3216cc1e8d831966241fc5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JKr5n4LkuMlKdEYCBjLkqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/53e70503ab3216cc1e8d831966241fc5","width":300,"height":53}},"lazy":false},{"type":"text","content":"Kuros Biosciences to provide investor updateat Octavian and Baader Bank Conferences","length":84,"tagName":"p"},{"type":"text","content":"Schlieren (Zürich), Switzerland, January 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced a series of milestones including key IDN (Integrated Delivery Network) health system approvals, significant regulatory approval, and published preclinical evidence supporting the continued adoption and global expansion of MagnetOs™, which are going to be presented at the Octavian Seminar 2026 and Baader Bank Swiss Equities Conference 2026.","length":500,"tagName":"p"},{"type":"text","content":"“These milestones reflect the strength and consistency of our strategy, building durable access through major U.S. health system approvals, achieving one of the most rigorous regulatory certifications globally, and continuing to expand a differentiated evidence portfolio for MagnetOs,” said Chris Fair, Chief Executive Officer of Kuros Biosciences. “Together, these achievements reinforce our position as an evidence driven biologics company and support the continued global adoption of MagnetOs as we execute on our long-term growth objectives.”","length":547,"tagName":"p"},{"type":"text","content":"Recent U.S. Healthcare System ApprovalsKuros announced that all five MagnetOs formulations have recently received approval across multiple large IDN health systems in the U.S., a critical step for access and adoption at scale.","length":227,"tagName":"p"},{"type":"text","content":"Health system approvals are typically granted following comprehensive evaluation by multidisciplinary stakeholders including clinical, supply chain, and value analysis teams. Such evaluations generally assess efficacy, safety, clinical performance, economic con...